The Food and Drug Administration is expected to grant full approval to the Alzheimer’s drug lecanemab by July 6. But access to the drug may still be limited.
(Image credit: National Institute on Aging, National Institutes of Health.)
An Alzheimer’s drug is on the way, but getting it may still be tough. Here’s why
